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Background: The LUCAS™ device delivers mechanical chest compressions that have been shown in experimental
studies to improve perfusion pressures to the brain and heart as well as augmenting cerebral blood flow and end
tidal CO2, compared with results from standard manual cardiopulmonary resuscitation (CPR). Two randomised pilot
studies in out-of-hospital cardiac arrest patients have not shown improved outcome when compared with manual
CPR. There remains evidence from small case series that the device can be potentially beneficial compared with
manual chest compressions in specific situations. This multicentre study is designed to evaluate the efficacy and
safety of mechanical chest compressions with the LUCAS™ device whilst allowing defibrillation during on-going
CPR, and comparing the results with those of conventional resuscitation.
Methods/design: This article describes the design and protocol of the LINC-study which is a randomised
controlled multicentre study of 2500 out-of-hospital cardiac arrest patients. The study has been registered at
ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00609778?term=LINC&rank=1).
Results: Primary endpoint is four-hour survival after successful restoration of spontaneous circulation. The safety
aspect is being evaluated by post mortem examinations in 300 patients that may reflect injuries from CPR.
Conclusion: This large multicentre study will contribute to the evaluation of mechanical chest compression in CPR
and specifically to the efficacy and safety of the LUCAS™ device when used in association with defibrillation during
on-going CPR.
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The LUCAS™ Chest Compression System (Physio-Control/
Jolife AB, Lund, Sweden) has been in clinical use since
2003. Experimental data have shown improved perfu-
sion pressures to the brain and heart, enhanced cerebral
blood flow and higher end tidal CO2 as an indirect
measure of cardiac output using the LUCAS™ device as
compared with the effects of conventional manual CPR
[1,2]. The LUCAS™ device has also shown higher end
tidal CO2 values in out-of-hospital cardiac arrest
(OHCA) victims compared with manual CPR [3]. There
is some evidence from small case series that the device
can be valuable in the catheterisation laboratory to
facilitate Percutaneous Coronary Intervention (PCI)
during cardiac arrest [4-6]. The potential benefit of the
device has also been reported in special circumstances
following accidental hypothermia/drowning and in
some cases of in-hospital cardiac arrest [6-12]. This was
recognised by the American and European guidelines
for resuscitation in 2010 [13,14].
However, in a cluster randomised pilot study of
OHCA patients, a comparison of manual versus mech-
anical chest compressions with the LUCAS™ device,
using the ACLS guideline from 2005, did not show any
outcome difference between the groups [15]. The study
was performed in a 2-tier ambulance system with a
6 min delay from the start of treatment to application of
LUCAS™ device and a substantial median interval
(18 min) from estimated time of cardiac arrest. Defibril-
lation was not delivered during on-going mechanical
chest compressions [15]. A second randomized pilot
study in OHCA victims was performed 2005–2007 in
Uppsala and Gävle, Sweden where the LUCAS™ device
was used in combination with defibrillation during on-
going chest compressions. It showed a trend to an
increased return of spontaneous circulation (ROSC) rate
(LUCAS = 40% vs. manual = 32%) despite interruptions
for rhythm analysis and a median (± SD) of 13.1 ±7.2 min
to start of mechanical chest compressions from estimated
time of cardiac arrest [16].
The LINC-study was designed using the knowledge
from previous studies, to evaluate the efficacy and safety
of mechanical chest compressions using LUCAS™, in
association with defibrillation during on-going CPR and
with reduced delays. It is powered to detect superiority
in four-hour survival of the modified resuscitation algo-
rithm compared with conventional manual resuscitation
in patients suffering from OHCA [13,14].
Methods and design of the LINC-study
Ethical approvals and study setting
The LINC-study is being conducted in accordance
with regulatory requirements, Good Clinical Practices
(GCP), and the ethical principles of the Declaration ofHelsinki as adopted by the 18th World Medical Assembly
in Helsinki, Finland in 1964. The study was approved by
the regional ethical review board in Uppsala, Sweden
(Dnr. 2007/271), a research ethics committee in England
(Dnr. 08/H0201/33), and the United Human Subjects
Research Committees (VCMO) in the Netherlands (Dnr.
NL 21034.10008. R-08.10E LINC). The study has been
registered at ClinicalTrials.gov (http://clinicaltrials.gov/ct2/
show/NCT00609778?term=LINC&rank=1) that supplies
information for locating federal and privately supported
clinical trials performed around the world.
Jolife AB, Lund, Sweden, the manufacturer of the
LUCAS™ device, was the initial sponsor of the study,
but since Jolife AB was acquired by Medtronic Inc.,
Minneapolis MN, USA (March 2011) and thereafter by
Physio-Control, Redmond WA, USA the sponsorship
was moved accordingly.
There are six participating Emergency Medical Services
(EMS) in the LINC-study; Gävle, Malmö, Västerås and
Uppsala in Sweden, Utrecht in the Netherlands, and Dorset
in England. These centres could fulfill the following
requirements: they have earlier experience of pre-
hospital studies or in the use of LUCAS™; they are not
participating in a clinical study that would be in conflict
with the LINC-study; they have responders who are able
to defibrillate manually rather than being restricted to
the use of Automated External Defibrillators (AEDs);
they enjoy good cooperation with their admitting hospitals;
their median response interval is relatively brief; the
number of patients who could be included was likely to
be at least 40 patients/year but not more than 400
patients/year; the hospital to which their patients are
admitted are able to perform PCI within 48 h following
ROSC; and all surviving patients could be treated with
hypothermia following ROSC, regardless of initial ECG
rhythm unless contraindicated. Six more EMS was
asked to participate but could not fulfill these criteria.
Demographic data of the six participating EMS are
presented in Table 1.
Steering committee and contract research organisation
(CRO)
The steering committee is monitoring the criteria for
termination stated in the study protocol, in which the
sponsor reserves the right to discontinue the study
before recruitment of the intended number of subjects,
but intends to exercise this right only for valid scien-
tific or administrative reasons. These are: unexpectedly
high proportion of adverse events; new findings about
the investigational product that changes the benefit/
risk ratio; the study protocol proves too difficult to
achieve; recruitment of eligible subjects is far too slow;
critical change in administrative or scientific standards
at the sponsor organisation or at the participating
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ence between the groups with a p-value from a two-
sided Fisher’s Exact Test of less than 0.005. The study
has a steering committee that has the following members:
1. Sten Rubertsson MD PhD, Uppsala, Sweden
(principal investigator)
2. Rolf Karlsten MD PhD, Uppsala, Sweden
3. Douglas Chamberlain MD, Brighton and Cardiff, UK
(advisor during the start-up and manuscript phases
only)
4. Johan Herlitz MD, PhD, Borås, Sweden
5. Anna Söderlund RN, Jolife AB, Lund, Sweden
(non-voting) (start-up phase-2008)
6. Ulrika Ericsson, RN, Jolife AB, Lund, Sweden
(non-voting) (from 2008)
7. Fredrik Arnwald, Director of clinical affairs,
Jolife AB, Lund, Sweden (non-voting).
Uppsala Clinical Research Center (UCR), Sweden was
appointed CRO to give advice on the outlines of the
study, to monitor the study, to give statistical advice, to
handle the database, and to perform the statistical ana-
lyses of the results. This will be done in accordance with
GCP for clinical trials.
Eligibility criteria for the study
Eligible patients for the LINC-study are adults with an
unexpected OHCA for whom an attempt of resuscitation is
considered appropriate.
The exclusion criteria are:
1. Traumatic cardiac arrest, including hanging
2. Age believed to be less than 18 years (no upper limit)
3. Known pregnancy
4. Defibrillated before LUCAS™ is brought to the scene
5. Patients body size not fitting the LUCAS™ System
Study enrolment and randomisation
The device is brought to all patients with dispatch codes
for sudden cardiac arrest, loss of consciousness, or otherlocal guidelines suggesting OHCA. Enrolment into the
study is at the time that paramedics recognise the situ-
ation as a cardiac arrest after they arrive on scene. After
confirmation of the arrest, one ambulance professional
immediately starts manual CPR while another takes care
of the randomisation procedure. All patients fulfilling
the inclusion criteria and having no known exclusion
criteria are randomised using block randomisation with
site (EMS) as stratification variable. Block size is set to
6, but has been kept unknown to all personnel involved
throughout the study. Randomisation is at the patient’s
side by opening an envelope which is enclosed in the
LUCAS™ back pack. Inside the envelope there will be a
note prompting either conventional manual or
LUCAS™ CPR. A replacement envelope from the block
of 6 is added to the LUCAS pack after each use.
Patients suffering a cardiac arrest witnessed by the
ambulance crew are handled according to a separate
algorithm and if eligible they are randomized into the
study (Figure 1).
Study algorithms and post-resuscitation care
Ventilation and the dosages of drugs in both groups are
given according to the International Consensus 2005 as
adopted by the European Resuscitation Council [13].
The LUCAS™ algorithm
Patients randomised to LUCAS™ CPR are treated initially
with manual compressions with minimised interruptions
until the device is unpacked and ready to use. LUCAS™ is
attached to the patient as soon as possible. In this group
the defibrillator must be in manual mode. Mechanical
compressions are continued initially for 3 min without
checking heart rhythm, irrespective of any manual
compressions that have been given by bystanders. The
sequence is not interrupted for a shock that is delivered
during compressions after 90 seconds of this first
3 min cycle, with the remaining 90 seconds of continued
compressions to follow. Thus, the first shock is given on
the basis only of definite cardiac arrest without know-
ledge of whether it is or is not ‘shockable’. Subsequently,
Sudden cardiac arrest  







AnalyzeROSC No ROSC Randomize to LINC
Asystoli / PEA
VF/VT
Figure 1 The separate algorithm used for patients suffering a cardiac arrest witnessed by the ambulance crew and used for these
witnessed cases for eligible judgment and randomisation into the LINC-study.
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interrupting mechanical compressions briefly and never
for longer than 10 seconds. If the analysed rhythm is
shockable, a new 3 min cycle of compressions is started,
incorporating as before one shock delivered after
90 seconds of on-going compressions. If the rhythm is
not shockable, a 3 min cycle of compressions without
any shock is followed by a new rhythm analysis. Heart
rhythm and circulation are checked after each
3 min cycle (Figure 2).
The conventional manual CPR algorithm
Those randomised to conventional manual CPR are














Figure 2 The LUCAS algorithm used in the LINC-study.2005 as adopted by the European Resuscitation Council
[13] (Figure 3).
Post resuscitation care
If the patient achieves ROSC, he/she should be treated
with mild hypothermia to 32–34 degrees Celsius for 24 h,
regardless of initial ECG rhythm, unless contraindications
exist. Acute coronary angiography should be considered
during the first 48 h of hospital admission.
Mechanical chest compression devices
Two models of LUCAS have been used during the study.
Initially, from January 2008 to early 2010, it was the




Adrenalin 1 mg i.v. or i.o.
After 3 defibrillations. 
There after every 3rd minute.
(Alternatively 3 mg in the
ET tube)
Amidarone 300 mg after 
4 defibrillations, 150 mg 
after 7 defibrillations
Patients with asystoli / PEA
Adrenalin 1 mg i.v. or i.o. 
as soon as possible, there after 
every 3rd minute.
(Alternatively 3mg in the 
ET tube)
Cardiac arrest witnessed by 
the ambulance crew, should if 
VT/VF be defibrillated x 1 





























• Correct reversible causes*





• Give uninterrupted 
compressions when airway 
secure
• Give Adrenalin every 3-5 min
• Consider: amiodarone, atropin ,  
magnesium
*Reversible Causes:
Hypoxia  Tension Pneumothorax
Hypovolaemia Tamponade, cardiac
Hypo/hyperkalaemia/Metabolic  Toxins
Hypothermia Thrombosis (coronary or pulmonary
Figure 3 The adult ALS algorithm used as control in the LINC-study.
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replaced by the LUCAS™ 2 Chest Compression System
which is powered electrically. Both devices achieve
mechanical chest compressions at a constant rate of 100
per minute and to a fixed depth of 4–5 cm by a piston
that has a 50% duty cycle, with the added feature of a
suction cup that may assist the chest back to neutral
position. The LUCAS™ 1 and LUCAS™ 2 devices used
in the study both adhere with the 2005 international
guidelines on resuscitation [13,14,17,18].
Patient consent
The nature of the study, in relation to patients who are
unconscious, precludes consent before enrolment. It is
the responsibility of the investigator to provide, for eachsurviving subject with mental capacity, full and adequate
verbal and written information about the objectives and
procedures of the study. They are given the opportunity
to ask questions and to decide whether or not they are
willing for their results to be included in the dataset.
They are also told of their freedom to withdraw from
the study at any time and that withdrawal will not affect
their future medical care. In cases where the subjects
survive without having the mental capacity to accept or
withdraw participation, written information is presented
to the family, who then take the decision to continue
participation or not. Subjects included who do not
survive will stay in the study; the family will not be asked
for consent. This prevents any positive bias in the
results.
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For efficacy evaluation the following primary and secondary
endpoints that will be analysed in the study are:
1. Primary endpoint
a. Four-hour survival after successful restoration of
spontaneous circulation (ROSC).2. Secondary endpoints
a. Restoration of spontaneous circulation defined as a
spontaneous palpable pulse.
b.Arrival to the emergency room with spontaneous
palpable pulse.
c. Survival to discharge from ICU without severe
neurological impairment (CPC 1 or 2).
d. Survival to hospital discharge without severe
neurological impairment (CPC 1 or 2).
e. Survival 1 and 6 months after cardiac arrest
without severe neurological impairment (CPC 1 or 2).The safety evaluation in the study comprises three
main areas. The first relates to serious adverse events or
serious adverse device events. These cover events directly
related to CPR, as judged by investigator/co-investigator,
and assumed to occur after the randomisation in the
study with any of the following sequelae: death; serious
deterioration of health in patient; life threatening illness
or injury, permanent deterioration of body function or
structure; prolongation of hospitalisation; conditions
that require medical or surgical treatment to prevent
any of the foregoing.
The second area for safety evaluation is any post
mortem examination that may reflect injuries from
CPR. For comparison of injuries from the two different
CPR techniques, autopsies are performed to quantify
the number of injuries possibly affecting survival. They
are undertaken in three centres (Uppsala, Gävle, and
Västerås in Sweden). The aim is to obtain autopsy
results from a total of 300 study patients with 150 who
have received manual chest compressions only and 150
after LUCAS™ chest compressions.
The third area relates to the criteria for termination of
the study stated in the protocol (described above) that
would be considered by the steering committee, spon-
sor, and the independent safety committee within the
Scandinavian Society of Anaesthesiology and Intensive
Care Medicine research group (SSAI).
Sample size and statistical methods
Considerations for the sample size calculations are
based upon data from the Uppsala-Gävle pilot study,
[15] together with data from the National Registry of
Cardiac Arrest in Sweden [19]. It was assumed that
in the conventional manual treatment group, the pro-
portion of four-hour survival will be 25% and in theLUCAS-CPR treatment group the proportion of four
hour survival will be at least 31%. To detect the antici-
pated difference of at least 6% with a power of 90% in
the final analysis, the study requires a total of 2500
patients, i.e. 1250 patients in each treatment group in
the intention to treat population. For the intention to
treat and predefined populations the primary and all
secondary endpoints will be compared between treatment
groups with frequency tables and two-sided Fisher’s Exact
Tests at the 4.8% and 5% level, respectively; 95% confidence
intervals for difference in proportions will be presented
where applicable. The result for the primary endpoint in
the intention to treat population is confirmative while the
other results are regarded as supportive.
Injuries after CPR will be studied in detail. The pro-
portions of patients will be compared between the two
treatment groups with frequency tables and two-sided
Fisher’s Exact Test at 5% level.Analysis populations
The analysis populations are defined as:
Safety population: all randomised patients except surviv-
ing patients without informed consent. Intention to treat
(ITT) population: all randomised patients except surviving
patients without informed consent. Predefined population
(PP): all randomised patients, except surviving patients
without informed consent, who have completed the study
treatment without any protocol violations. Possible protocol
violations are:
 Inclusion criterion not fulfilled.
 Primary exclusion criteria subsequently confirmed to
have been present.
 Dispatch time to ambulance stop at the address
exceeding 12 min.
 Cardiac arrest not witnessed by sight or sound
(If data are missing regarding whether the cardiac
arrest was witnessed or not, the patient should be
regarded as not witnessed).
 LUCAS™ Chest Compression System not brought
to the patient or no record form filled in.
If the actual treatment given is not that to which the
patient was randomised, the patient will be included in
the ITT population set as randomised, but in the PP
population according to the actual treatment.
For missing data, the primary endpoint and the first
four of the secondary endpoints will be defined accord-
ing to the worst case principle, i.e. as failures in the ITT
population. The confirmative analysis will be performed
in the ITT population. The PP analysis will be regarded
as supportive. In the PP analysis no imputation of miss-
ing values will be performed.
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formed during spring 2011 by an independent safety com-
mittee within the Scandinavian Society of Anaesthesiology
and Intensive Care Medicine research group (SSAI).
This was done according to protocol, after 1500 patients
had been randomized, using the primary endpoint i.e.
4 h of ROSC, and performed on the intention to treat
population. In the interim analysis the criterion for ter-
minating the study is that the p-value from a two-sided
Fisher’s Exact Test is less than 0.005. A group-sequen-
tial analysis plan [20] is used to preserve a Type I error
of at most 5%, so that after completion of the study the
primary hypothesis will be tested at a level of 4.8%.
Data management and source data
The Biometrics section at UCR is responsible for the
Data Management and has written a study specific
Data Management Plan and a Data Validation Plan. All
data is recorded in the Clinical Report Forms (CRFs)
and entered via e-CRF directly into a web-based data
capturing system. All CRF data is entered into the
e-CRF system by the study coordinators at each site.
Study data found in either the hospital records or in
the paper CRF is considered to be source data. The
source data verification ensures consistency between
the e-CRF and the paper CRF/patient hospital file.
Training
Before the study started, all paramedics and other am-
bulance personnel at each site were trained in conven-
tional manual CPR according to the 2005 guidelines, in
the use of LUCAS™ Chest Compressions System, and in
the algorithms of the two different treatments [13,14].
The training with the LUCAS™ device was supervised
by personnel from the sponsor. Retraining for both
techniques continues at least every 6 months during the
study period. Personnel involved in the study at the
emergency department and at other wards inside the
hospital are trained according to the requirements at
different sites. Training results for both techniques have
been monitored once every year in randomly selected
personnel (20%–30%) using a modified CPR manikin
(Laerdal, Stavanger, Norway) which measures quality of
compressions. This training evaluation has been per-
formed and documented annually from 2009 to 2012.
Discussion
The LINC-study is the first large multicentre trial powered
to evaluate short term survival using mechanical chest
compressions with the LUCAS™ device compared with
manual chest compressions following conventional
guidelines [13,14]. It is being conducted on adult OHCA
victims, excluding those who have initial shock success
following crew witnessed cardiac arrest or those whohave been treated with bystander defibrillation before
the arrival of the ambulance service. These groups have
a relatively good prognosis. Their exclusion will intro-
duce a negative bias on overall survival in the study, but
it will not influence the comparison between the two
groups.
The LINC protocol was modified after the Uppsala-Gävle
pilot from that originally envisaged in relation to defib-
rillation strategy [16]. The study as performed uses
shocks without analyse during uninterrupted chest
compressions for the first sequence in the LUCAS™
group regardless of underlying rhythm, with increased
emphasis of having the device on the patient earlier
than in the two previous OHCA studies [15,16]. The
rationale for having this first shock without analyse in
the group treated with LUCAS-CPR is to allow earlier
possibility of return of coordinated rhythm in patients
with VF/VT. Patients with an initial non-shockable
rhythm therefore have one unnecessary shock. The pos-
sible harm of this has been extensively discussed within
the steering committee after careful evaluation of what
is known from the literature, but also after discussion
with other experts in the field. The consensus reached
has been that the shock without analyse has more
potential for benefit than for harm. A further cogent
reason for both the initial shock without analyse and for
giving a shock halfway through other sequences after
detection of a shockable rhythm relates to the known
need for the perishock pauses to be a brief as possible
[21]. In the LUCAS™ treatment arm, these pauses can
be eliminated.
Since no ECG analysis is done before the first defibril-
lation in the treatment group, a best estimate of the
‘pre-shock ECG rhythm’ is achieved as follows: if a
patient has either a pulse or ventricular fibrillation after
the first shock, it will be assumed that this patient had
ventricular fibrillation before the first shock; if the
patient has either asystole or pulseless electrical activity
after the first shock, it will be assumed that these
patients had the same rhythm before the first shock
attempt. ‘Pre-shock’ ECG will be noted in the CRF
according to this best estimate.
No other large randomised study using a mechanical
chest compression device has been performed or is planned
that includes a comparison of injuries from the two differ-
ent CPR techniques as shown by autopsy [22-24], which is
important when placing any new techniques into a clinical
context [25]. The safety of the LUCAS™ device has been
studied only in small randomised studies and these have
not shown any significant differences between manual
or mechanical chest compressions despite the concerns
that have been raised for this type of treatment [26,27].
A further test of the validity of these results is therefore
warranted. It should be noted, however, that even the
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have had a period of manual chest compressions before
the device was applied, and this could contribute to any
injury.
This study has used CPR training intervals similar to
those practised in the clinical setting of most EMS in
the world, but to ensure quality in both study arms the
actual training procedures have been evaluated in
randomly selected personnel at each site, as described
above.
From spring 2010, the LUCAS™ 1 Chest Compression
System was replaced in the study by the LUCAS™ 2
device. This change was made after discussion between
the steering committee and the sponsor, and was
approved by all of the independent ethics committees.
The rationale supporting this decision was that the
performance of these two versions of LUCAS™ devices
provides mechanical chest compressions with the same
rate, depth, duty cycle, and recoil of the chest. This
change of device resulted in a few potential benefits for
the ambulance crews. They do not need to carry a tank
of pressured air, weighing 6.8 kg, which was the power
source to LUCAS™ 1. The power source of the LUCAS™
2 is instead an integrated battery with a weight of 0.6 kg.
Secondly, the LUCAS™ 2 is also able to perform chest
compressions in 30:2 mode.
During the spring of 2011 the planned interim analysis
of the LINC-study was carried out by the Scandinavian
Society of Anaesthesiology and Intensive Care Medicine
research group. The results of the analysis allowed the
study to continue, a decision endorsed by the LINC
steering committee. This means that the enrolment
continued and the final patient was enrolled in the end
of August, 2012, with complete outcome data available
6 month later. The results are expected to be published
in a scientific journal during 2013.Conclusion
The LINC-study was designed to evaluate the efficacy
and safety of a resuscitation method for OHCA using
mechanical chest compressions with the LUCAS™ de-
vice associated with defibrillation during compression
and to compare the results with those of manual CPR
according to 2005 guidelines. As a large randomised
multicentre study, it will contribute to knowledge of
OHCA and to the role of the mechanical chest com-
pression with LUCAS™.
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